Neva is now reimbursable in France!
With great satisfaction, we announce that the Vesalius NeVa thrombectomy system is now reimbursable in France starting November 14, 2024!
Since its launch in 2018, NeVa has been used in more than 12,000 cases worldwide, offering exceptional first-pass recanalization rates and demonstrating efficacy on all clot types.
The CLEAR study further confirmed these results, demonstrating improved outcomes compared with reference devices.
Contact us to receive full details about Neva and NevaNet devices.
Neva and NevaNet are CE approved.
Since its launch in 2018, NeVa has been used in more than 12,000 cases worldwide, offering exceptional first-pass recanalization rates and demonstrating efficacy on all clot types.
The CLEAR study further confirmed these results, demonstrating improved outcomes compared with reference devices.
Contact us to receive full details about Neva and NevaNet devices.
Neva and NevaNet are CE approved.
